Medicine

Lessons from an adverse gene therapy trial for Duchenne muscular dystrophy

.Attributes Medicine, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA approval after a damaging test, which highlights the various intricacies as well as challenges of medication advancement within this environment.

Articles You Can Be Interested In